ライム病診断薬市場(診断テスト:診断テスト:血清学的テスト、ポリメラーゼ連鎖反応[PCR]テスト、その他;およびサンプル:世界の産業分析、市場規模、シェア、成長、動向、予測、2023-2031年Lyme Disease Diagnostics Market (Diagnostic Test: Serological Test, Polymerase Chain Reaction [PCR] Test, and Others; and Sample: Blood, Cerebrospinal Fluid [CSF], and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031 ライム病診断薬市場 - レポートの範囲 TMRの調査レポート「世界のライム病診断薬市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリーライム病診断薬市場 - レポートの範囲TMRの調査レポート「世界のライム病診断薬市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会を調査しています。2023年を基準年、2031年を予測年として、2017年から2031年までの世界のライム病診断薬市場の収益を提供しています。また、2023年から2031年までの世界のライム病診断薬市場の複合年間成長率(CAGR %)も掲載しています。 本レポートは広範な調査を経て作成されました。主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、ライム病診断薬市場を理解するために、主要企業の製品資料、年次報告書、プレスリリース、関連文書を参照した。 二次調査には、インターネット情報源、政府機関の統計データ、ウェブサイト、業界団体なども含まれます。アナリストは、世界のライム病診断薬市場の様々な属性を調査するために、トップダウンアプローチとボトムアップアプローチの組み合わせを採用しました。 本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、本レポートは、世界のライム病診断薬市場における競争ダイナミクスの変化に光を投げかけています。これらは、既存の市場プレイヤーだけでなく、世界のライム病診断薬市場への参入に関心のある企業にとっても貴重なツールとなります。 本レポートでは、世界のライム病診断薬市場の競争環境について掘り下げています。世界のライム病診断薬市場で事業を展開する主要企業が特定され、これらの各企業が様々な属性でプロファイリングされています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界のライム病診断薬市場におけるプレイヤーの属性である。 世界のライム病診断薬市場レポートで回答された主な質問 - 予測期間中の全地域におけるライム病診断薬の売上高/収益は? - 世界のライム病診断薬市場におけるビジネスチャンスは? - 市場における主な促進要因、阻害要因、機会、脅威は何か? - 予測期間中に最も速いCAGRで拡大する地域市場はどこか? - 2031年に世界で最も高い収益を上げると予測されるセグメントは? - 予測期間中に最も高いCAGRで拡大すると予測されるセグメントは? - 世界市場で事業を展開する各企業の市場ポジションは? ライム病診断薬市場 - 調査目的と調査アプローチ ライム病診断薬の世界市場に関する包括的なレポートは、概要から始まり、調査範囲と目的が続きます。本レポートでは、本調査の目的、市場で事業を展開する主要ベンダーと流通業者、製品の承認に関する規制シナリオについて詳細に説明しています。 本レポートは、読みやすさを考慮し、各セクションを章ごとに分割したレイアウトになっています。本レポートは、グラフや表が適切に散りばめられた網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴える。また、過去と予測期間末の主要セグメントの市場シェアを比較することもできる。 本レポートでは、世界のライム病診断薬市場を製品、エンドユーザー、地域の観点から分析している。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアを掲載しています。このような貴重な洞察により、市場関係者は世界のライム病診断薬市場への投資について、情報に基づいたビジネス上の意思決定を行うことが可能となります。 目次1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Lyme Disease Diagnostics Market 4. Market Overview 4.1. Introduction 4.1.1. Segment Definition 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Lyme Disease Diagnostics Market Analysis and Forecast, 2017-2031 4.4.1. Market Revenue Projection (US$ Mn) 5. Key Insights 5.1. Innovations in Diagnostic Testing for Lyme disease 5.2. Incidence and Prevalence of Lyme Disease 5.3. Regulatory Scenario by Region/Globally 5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long Term Impact) 6. Global Lyme Disease Diagnostics Market Analysis and Forecast, by Diagnostic Test 6.1. Introduction & Definition 6.2. Key Findings/Developments 6.3. Market Value Forecast, by Diagnostic Test, 2017-2031 6.3.1. Serological Test 6.3.1.1. ELISA 6.3.1.2. Western Blot 6.3.2. Polymerase Chain Reaction (PCR) test 6.3.3. Others 6.4. Market Attractiveness Analysis, by Diagnostic Test 7. Global Lyme Disease Diagnostics Market Analysis and Forecast, by Sample 7.1. Introduction & Definition 7.2. Key Findings/Developments 7.3. Market Value Forecast, by Sample, 2017-2031 7.3.1. Blood 7.3.2. Cerebrospinal Fluid (CSF) 7.3.3. Others 7.4. Market Attractiveness Analysis, by Sample 8. Global Lyme Disease Diagnostics Market Analysis and Forecast, by End-user 8.1. Introduction & Definition 8.2. Key Findings/Developments 8.3. Market Value Forecast, by End-user, 2017-2031 8.3.1. Hospitals 8.3.2. Diagnostic Laboratories 8.3.3. Others 8.4. Market Attractiveness Analysis, by End-user 9. Global Lyme Disease Diagnostics Market Analysis and Forecast, by Region 9.1. Key Findings 9.2. Market Value Forecast, by Region, 2017-2031 9.2.1. North America 9.2.2. Europe 9.2.3. Asia Pacific 9.2.4. Latin America 9.2.5. Middle East & Africa 9.3. Market Attractiveness Analysis, by Region 10. North America Lyme Disease Diagnostics Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.2. Market Value Forecast, by Diagnostic Test, 2017-2031 10.2.1. Serological Test 10.2.1.1. ELISA 10.2.1.2. Western Blot 10.2.2. Polymerase Chain Reaction (PCR) test 10.2.3. Others 10.3. Market Value Forecast, by Sample, 2017-2031 10.3.1. Blood 10.3.2. Cerebrospinal Fluid (CSF) 10.3.3. Others 10.4. Market Value Forecast, by End-user, 2017-2031 10.4.1. Hospitals 10.4.2. Diagnostic Laboratories 10.4.3. Others 10.5. Market Value Forecast, by Country, 2017-2031 10.5.1. U.S. 10.5.2. Canada 10.6. Market Attractiveness Analysis 10.6.1. By Diagnostic Test 10.6.2. By Sample 10.6.3. By End-user 10.6.4. By Country 11. Europe Lyme Disease Diagnostics Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Diagnostic Test, 2017-2031 11.2.1. Serological Test 11.2.1.1. ELISA 11.2.1.2. Western Blot 11.2.2. Polymerase Chain Reaction (PCR) test 11.2.3. Others 11.3. Market Value Forecast, by Sample, 2017-2031 11.3.1. Blood 11.3.2. Cerebrospinal Fluid (CSF) 11.3.3. Others 11.4. Market Value Forecast, by End-user, 2017-2031 11.4.1. Hospitals 11.4.2. Diagnostic Laboratories 11.4.3. Others 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031 11.5.1. Germany 11.5.2. U.K. 11.5.3. France 11.5.4. Italy 11.5.5. Spain 11.5.6. Rest of Europe 11.6. Market Attractiveness Analysis 11.6.1. By Diagnostic Test 11.6.2. By Sample 11.6.3. By End-user 11.6.4. By Country/Sub-region 12. Asia Pacific Lyme Disease Diagnostics Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Diagnostic Test, 2017-2031 12.2.1. Serological Test 12.2.1.1. ELISA 12.2.1.2. Western Blot 12.2.2. Polymerase Chain Reaction (PCR) test 12.2.3. Others 12.3. Market Value Forecast, by Sample, 2017-2031 12.3.1. Blood 12.3.2. Cerebrospinal Fluid (CSF) 12.3.3. Others 12.4. Market Value Forecast, by End-user, 2017-2031 12.4.1. Hospitals 12.4.2. Diagnostic Laboratories 12.4.3. Others 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031 12.5.1. China 12.5.2. Japan 12.5.3. India 12.5.4. Australia & New Zealand 12.5.5. Rest of Asia Pacific 12.6. Market Attractiveness Analysis 12.6.1. By Diagnostic Test 12.6.2. By Sample 12.6.3. By End-user 12.6.4. By Country/Sub-region 13. Latin America Lyme Disease Diagnostics Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Diagnostic Test, 2017-2031 13.2.1. Serological Test 13.2.1.1. ELISA 13.2.1.2. Western Blot 13.2.2. Polymerase Chain Reaction (PCR) test 13.2.3. Others 13.3. Market Value Forecast, by Sample, 2017-2031 13.3.1. Blood 13.3.2. Cerebrospinal Fluid (CSF) 13.3.3. Others 13.4. Market Value Forecast, by End-user, 2017-2031 13.4.1. Hospitals 13.4.2. Diagnostic Laboratories 13.4.3. Others 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031 13.5.1. Brazil 13.5.2. Mexico 13.5.3. Rest of Latin America 13.6. Market Attractiveness Analysis 13.6.1. By Diagnostic Test 13.6.2. By Sample 13.6.3. By End-user 13.6.4. By Country/Sub-region 14. Middle East & Africa Lyme Disease Diagnostics Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Diagnostic Test, 2017-2031 14.2.1. Serological Test 14.2.1.1. ELISA 14.2.1.2. Western Blot 14.2.2. Polymerase Chain Reaction (PCR) test 14.2.3. Others 14.3. Market Value Forecast, by Sample, 2017-2031 14.3.1. Blood 14.3.2. Cerebrospinal Fluid (CSF) 14.3.3. Others 14.4. Market Value Forecast, by End-user, 2017-2031 14.4.1. Hospitals 14.4.2. Diagnostic Laboratories 14.4.3. Others 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031 14.5.1. GCC Countries 14.5.2. South Africa 14.5.3. Rest of Middle East & Africa 14.6. Market Attractiveness Analysis 14.6.1. By Diagnostic Test 14.6.2. By Sample 14.6.3. By End-user 14.6.4. By Country/Sub-region 15. Competition Landscape 15.1. Market Player - Competition Matrix (By Tier and Size of Companies) 15.2. Market Share Analysis, by Company (2022) 15.3. Company Profiles 15.3.1. LabCorp 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.1.2. Product Portfolio 15.3.1.3. Financial Overview 15.3.1.4. SWOT Analysis 15.3.1.5. Strategic Overview 15.3.2. Quest Diagnostics 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.2.2. Product Portfolio 15.3.2.3. Financial Overview 15.3.2.4. SWOT Analysis 15.3.2.5. Strategic Overview 15.3.3. Abbott Laboratories 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.3.2. Product Portfolio 15.3.3.3. Financial Overview 15.3.3.4. SWOT Analysis 15.3.3.5. Strategic Overview 15.3.4. Bio-Rad Laboratories, Inc. 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.4.2. Product Portfolio 15.3.4.3. Financial Overview 15.3.4.4. SWOT Analysis 15.3.4.5. Strategic Overview 15.3.5. bioMérieux SA 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.5.2. Product Portfolio 15.3.5.3. Financial Overview 15.3.5.4. SWOT Analysis 15.3.5.5. Strategic Overview 15.3.6. DiaSorin S.p.A. 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.6.2. Product Portfolio 15.3.6.3. Financial Overview 15.3.6.4. SWOT Analysis 15.3.6.5. Strategic Overview 15.3.7. T2 Biosystems, Inc. 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.7.2. Product Portfolio 15.3.7.3. Financial Overview 15.3.7.4. SWOT Analysis 15.3.7.5. Strategic Overview 15.3.8. F. Hoffmann-La Roche AG 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.8.2. Product Portfolio 15.3.8.3. Financial Overview 15.3.8.4. SWOT Analysis 15.3.8.5. Strategic Overview 15.3.9. Meridian Bioscience, Inc. 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.9.2. Product Portfolio 15.3.9.3. Financial Overview 15.3.9.4. SWOT Analysis 15.3.9.5. Strategic Overview 15.3.10. Quidel Corporation 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.10.2. Product Portfolio 15.3.10.3. Financial Overview 15.3.10.4. SWOT Analysis 15.3.10.5. Strategic Overview
SummaryLyme Disease Diagnostics Market – Scope of Report Table of Contents1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Lyme Disease Diagnostics Market 4. Market Overview 4.1. Introduction 4.1.1. Segment Definition 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Lyme Disease Diagnostics Market Analysis and Forecast, 2017-2031 4.4.1. Market Revenue Projection (US$ Mn) 5. Key Insights 5.1. Innovations in Diagnostic Testing for Lyme disease 5.2. Incidence and Prevalence of Lyme Disease 5.3. Regulatory Scenario by Region/Globally 5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long Term Impact) 6. Global Lyme Disease Diagnostics Market Analysis and Forecast, by Diagnostic Test 6.1. Introduction & Definition 6.2. Key Findings/Developments 6.3. Market Value Forecast, by Diagnostic Test, 2017-2031 6.3.1. Serological Test 6.3.1.1. ELISA 6.3.1.2. Western Blot 6.3.2. Polymerase Chain Reaction (PCR) test 6.3.3. Others 6.4. Market Attractiveness Analysis, by Diagnostic Test 7. Global Lyme Disease Diagnostics Market Analysis and Forecast, by Sample 7.1. Introduction & Definition 7.2. Key Findings/Developments 7.3. Market Value Forecast, by Sample, 2017-2031 7.3.1. Blood 7.3.2. Cerebrospinal Fluid (CSF) 7.3.3. Others 7.4. Market Attractiveness Analysis, by Sample 8. Global Lyme Disease Diagnostics Market Analysis and Forecast, by End-user 8.1. Introduction & Definition 8.2. Key Findings/Developments 8.3. Market Value Forecast, by End-user, 2017-2031 8.3.1. Hospitals 8.3.2. Diagnostic Laboratories 8.3.3. Others 8.4. Market Attractiveness Analysis, by End-user 9. Global Lyme Disease Diagnostics Market Analysis and Forecast, by Region 9.1. Key Findings 9.2. Market Value Forecast, by Region, 2017-2031 9.2.1. North America 9.2.2. Europe 9.2.3. Asia Pacific 9.2.4. Latin America 9.2.5. Middle East & Africa 9.3. Market Attractiveness Analysis, by Region 10. North America Lyme Disease Diagnostics Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.2. Market Value Forecast, by Diagnostic Test, 2017-2031 10.2.1. Serological Test 10.2.1.1. ELISA 10.2.1.2. Western Blot 10.2.2. Polymerase Chain Reaction (PCR) test 10.2.3. Others 10.3. Market Value Forecast, by Sample, 2017-2031 10.3.1. Blood 10.3.2. Cerebrospinal Fluid (CSF) 10.3.3. Others 10.4. Market Value Forecast, by End-user, 2017-2031 10.4.1. Hospitals 10.4.2. Diagnostic Laboratories 10.4.3. Others 10.5. Market Value Forecast, by Country, 2017-2031 10.5.1. U.S. 10.5.2. Canada 10.6. Market Attractiveness Analysis 10.6.1. By Diagnostic Test 10.6.2. By Sample 10.6.3. By End-user 10.6.4. By Country 11. Europe Lyme Disease Diagnostics Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Diagnostic Test, 2017-2031 11.2.1. Serological Test 11.2.1.1. ELISA 11.2.1.2. Western Blot 11.2.2. Polymerase Chain Reaction (PCR) test 11.2.3. Others 11.3. Market Value Forecast, by Sample, 2017-2031 11.3.1. Blood 11.3.2. Cerebrospinal Fluid (CSF) 11.3.3. Others 11.4. Market Value Forecast, by End-user, 2017-2031 11.4.1. Hospitals 11.4.2. Diagnostic Laboratories 11.4.3. Others 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031 11.5.1. Germany 11.5.2. U.K. 11.5.3. France 11.5.4. Italy 11.5.5. Spain 11.5.6. Rest of Europe 11.6. Market Attractiveness Analysis 11.6.1. By Diagnostic Test 11.6.2. By Sample 11.6.3. By End-user 11.6.4. By Country/Sub-region 12. Asia Pacific Lyme Disease Diagnostics Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Diagnostic Test, 2017-2031 12.2.1. Serological Test 12.2.1.1. ELISA 12.2.1.2. Western Blot 12.2.2. Polymerase Chain Reaction (PCR) test 12.2.3. Others 12.3. Market Value Forecast, by Sample, 2017-2031 12.3.1. Blood 12.3.2. Cerebrospinal Fluid (CSF) 12.3.3. Others 12.4. Market Value Forecast, by End-user, 2017-2031 12.4.1. Hospitals 12.4.2. Diagnostic Laboratories 12.4.3. Others 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031 12.5.1. China 12.5.2. Japan 12.5.3. India 12.5.4. Australia & New Zealand 12.5.5. Rest of Asia Pacific 12.6. Market Attractiveness Analysis 12.6.1. By Diagnostic Test 12.6.2. By Sample 12.6.3. By End-user 12.6.4. By Country/Sub-region 13. Latin America Lyme Disease Diagnostics Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Diagnostic Test, 2017-2031 13.2.1. Serological Test 13.2.1.1. ELISA 13.2.1.2. Western Blot 13.2.2. Polymerase Chain Reaction (PCR) test 13.2.3. Others 13.3. Market Value Forecast, by Sample, 2017-2031 13.3.1. Blood 13.3.2. Cerebrospinal Fluid (CSF) 13.3.3. Others 13.4. Market Value Forecast, by End-user, 2017-2031 13.4.1. Hospitals 13.4.2. Diagnostic Laboratories 13.4.3. Others 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031 13.5.1. Brazil 13.5.2. Mexico 13.5.3. Rest of Latin America 13.6. Market Attractiveness Analysis 13.6.1. By Diagnostic Test 13.6.2. By Sample 13.6.3. By End-user 13.6.4. By Country/Sub-region 14. Middle East & Africa Lyme Disease Diagnostics Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Diagnostic Test, 2017-2031 14.2.1. Serological Test 14.2.1.1. ELISA 14.2.1.2. Western Blot 14.2.2. Polymerase Chain Reaction (PCR) test 14.2.3. Others 14.3. Market Value Forecast, by Sample, 2017-2031 14.3.1. Blood 14.3.2. Cerebrospinal Fluid (CSF) 14.3.3. Others 14.4. Market Value Forecast, by End-user, 2017-2031 14.4.1. Hospitals 14.4.2. Diagnostic Laboratories 14.4.3. Others 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031 14.5.1. GCC Countries 14.5.2. South Africa 14.5.3. Rest of Middle East & Africa 14.6. Market Attractiveness Analysis 14.6.1. By Diagnostic Test 14.6.2. By Sample 14.6.3. By End-user 14.6.4. By Country/Sub-region 15. Competition Landscape 15.1. Market Player - Competition Matrix (By Tier and Size of Companies) 15.2. Market Share Analysis, by Company (2022) 15.3. Company Profiles 15.3.1. LabCorp 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.1.2. Product Portfolio 15.3.1.3. Financial Overview 15.3.1.4. SWOT Analysis 15.3.1.5. Strategic Overview 15.3.2. Quest Diagnostics 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.2.2. Product Portfolio 15.3.2.3. Financial Overview 15.3.2.4. SWOT Analysis 15.3.2.5. Strategic Overview 15.3.3. Abbott Laboratories 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.3.2. Product Portfolio 15.3.3.3. Financial Overview 15.3.3.4. SWOT Analysis 15.3.3.5. Strategic Overview 15.3.4. Bio-Rad Laboratories, Inc. 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.4.2. Product Portfolio 15.3.4.3. Financial Overview 15.3.4.4. SWOT Analysis 15.3.4.5. Strategic Overview 15.3.5. bioMérieux SA 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.5.2. Product Portfolio 15.3.5.3. Financial Overview 15.3.5.4. SWOT Analysis 15.3.5.5. Strategic Overview 15.3.6. DiaSorin S.p.A. 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.6.2. Product Portfolio 15.3.6.3. Financial Overview 15.3.6.4. SWOT Analysis 15.3.6.5. Strategic Overview 15.3.7. T2 Biosystems, Inc. 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.7.2. Product Portfolio 15.3.7.3. Financial Overview 15.3.7.4. SWOT Analysis 15.3.7.5. Strategic Overview 15.3.8. F. Hoffmann-La Roche AG 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.8.2. Product Portfolio 15.3.8.3. Financial Overview 15.3.8.4. SWOT Analysis 15.3.8.5. Strategic Overview 15.3.9. Meridian Bioscience, Inc. 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.9.2. Product Portfolio 15.3.9.3. Financial Overview 15.3.9.4. SWOT Analysis 15.3.9.5. Strategic Overview 15.3.10. Quidel Corporation 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.10.2. Product Portfolio 15.3.10.3. Financial Overview 15.3.10.4. SWOT Analysis 15.3.10.5. Strategic Overview
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
Transparency Market Research社の医療分野での最新刊レポート
本レポートと同じKEY WORD(diagnostic)の最新刊レポート
よくあるご質問Transparency Market Research社はどのような調査会社ですか?トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|